Hear from other medical professionals who treat atopic dermatitis

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Please view entire video for clinical trial efficacy and safety data and for full Important Safety Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi. I’m Dr Jim Del Rosso, and this is the Beyond the Surface series.

    Today on the green couch, I’m very pleased to welcome Dr Dareen Siri, an allergist from Springfield, Illinois.

    Hello, Jim. It’s really great to be here. Thank you for inviting me.

    It’s a pleasure.

    So as a dermatologist, I see atopic dermatitis. As an allergist, you see atopic dermatitis. And the patients could come to either one of us to see the same disease. And I actually like talking to allergists because you have some background in your training that we in dermatology don’t have. So we can share a lot of important information, because it’s obviously a tough disease.

    I think those are definitely great points you make.

    This patient I have been taking care of for a while, I took care of her when she started seeing us some years ago as a teenager. At the time, she did have moderate atopic dermatitis, but certainly had had a number of different therapies prior to us seeing her. She had definitely seen dermatology as well as family practice in the past.

    This female patient is part Latina. Not only did she have the usual characteristics of atopic dermatitis, with redness, lichenification. She had areas of excoriation. She had active disease.

    In this case, when the patient came in the first time, what was most bothersome to them? How much was the itching a part of it?

    She felt like she had dragon skin because her skin was inflamed. It was fiery. Sometimes it burned, and it was really, really irritating and itchy.

    So now you’re with this patient, and they failed prescription topicals. How did that first conversation go with the patient? And how did you explain this specific therapy, the DUPIXENT therapy?

    I think patients really get it when we talk about the fact that it targets specifically the cytokines IL-4 and IL-13 signaling, and this may address the inflammatory underlying problem.

    I think safety profile is really, really important. So that was one of the key players in this therapeutic option and making that decision with the family.

    [Narrator VO of on-screen adverse events; no captioning necessary]

    So now you’ve initiated DUPIXENT therapy in this patient, and so, what did you see in this patient?

    She had a really remarkable change. She had reduction of itch, which then led to that cascade of improved treatment course for atopic dermatitis and those additional lesions.

    And she has been on that therapy and sustained, and really has continued to have skin clearance.

    Thank you, Dareen, for this great discussion, and for sharing your experiences with this patient.

    Thank you so much, Jim, for having me today, and I appreciate being able to talk about my patient’s experience and her wonderful result with DUPIXENT today.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi. I’m Dr Jim Del Rosso, and this is the Beyond the Surface series.

    Today on the green couch, it’s a pleasure to have with us Dr Ben Lockshin, who is a board-certified dermatologist practicing in Silver Spring, Maryland.

    Jim, it’s nice to see you and it’s a pleasure to be here to talk about DUPIXENT in atopic dermatitis.

    So, Ben, now let’s talk about the case, or I should actually say cases that you’re bringing to discuss with me today.

    One is the son who has severe atopic dermatitis, the other is the father that has moderate atopic dermatitis. So let’s start with the son first.

    Jim, I’d been following a family for a number of years where the son had severe atopic dermatitis since early childhood.

    He had lost hope, plagued with itch, where the itch seemed to be just as disruptive as the skin changes.

    The excoriations, the erythema, the redness he had, and the lichenification, the thickening of the skin that he was experiencing.

    And what is it in the history that leads you to think about it’s time to step up to DUPIXENT therapy?

    Prior to the initiation of DUPIXENT, the son was on various topical prescription therapies, including topical corticosteroids and calcineurin inhibitors. In addition, he was on numerous systemic immunosuppressive agents.

    So all the conventional treatments, but it wasn’t adequate control.

    When I brought it up, actually I was surprised, because the parents were more on board than the son. I really had to coach him through the idea of being on an injectable medication.

    When I talk about the safety profile with patients, I really like to highlight the fact that this drug was studied in various different age groups.

    [Narrator VO of on-screen adverse events; no captioning necessary]

    So, what about the discussion that there’s no need for any baseline laboratory monitoring or testing?

    There are a number of things that really resonate with the patients, and one of them is the lack of laboratory monitoring.

    Not having any black box warnings is another thing that really resonates with patients, that this is not a steroid, it’s not an immunosuppressant.

    The patients don’t know that, and many of them are apprehensive because they think that this is.

    You initiated DUPIXENT therapy, and when did you see them back? And when did they start noticing, for example, an improvement in the itch?

    I remember when he came back about 6 months later, and he said, “Why didn’t I do this earlier?” And he was just over-the-moon happy. And his mother, she was over the moon.

    So not only did he have significant reduction of itch, but his skin looked significantly better, really going from an IGA of 4, which he had lived with an IGA of 4 almost consistently for years, down to virtual clearance.

    You’re describing that the parents are watching their kid go through this. Can you capsulize the story of what happened with the father who had moderate-severity disease?

    He was frustrated by the amount of creams that he had to apply, the number of treatments that he needed to cycle through. He got to see firsthand the efficacy of the product.

    He came in, and just during a regular visit he said, “I never have a moment where I don’t have any atopic dermatitis, even though mine was not nearly as bad as my son’s. Would I be a candidate for DUPIXENT as well?”

    And I said, “Actually, you’d be an excellent candidate.”

    After initiating DUPIXENT, he stated that his itch was dramatically better. And during today’s visit he reported that his skin was clear.

    Ben, thank you for these two excellent cases of atopic dermatitis, one an adolescent that obviously battled severe disease, and then the father, who got to observe the improvement in the son and was actually motivated to come to you and ask for the therapy and did very well with more moderate severity.

    Treatment choices in severe patients are a lot easier to kind of navigate because, I think all, you know, indicators are pointing towards a systemic therapy like DUPIXENT.

    But those moderate patients putting topical steroids on and going through the motions day by day and still having lingering disease, those are just as good of a candidate as the really bad patients.

    So, Ben, I want to really thank you for everything you shared today. These were two great cases, different situations, so it brings to light what some of the different discussions are. So I really appreciate your time in sharing this with us. Thank you.

    Well, Jim, thanks for inviting me. It’s a pleasure to be here.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I’m Dr Jim Del Rosso, and this is the Beyond the Surface series.

    Today on the green couch, we’re pleased to have with us Gina Mangin, a dermatology physician assistant who practices in Orlando, Florida. Gina, it’s great to see you today.

    Hi Dr Del Rosso, it’s so great to see you as well.

    I’d like to start by asking you what’s a day in the life of Gina Mangin, as a physician assistant?

    So, I’ve been practicing dermatology for 13 years. As a PA, I diagnose, I treat, and I manage dermatological conditions; that includes atopic dermatitis. Any kind of aspect of medical dermatology, I am there to assist our team in taking care of our patients.

    So, Gina, let’s get down to the nitty-gritty and talk about the patient you want to discuss with us today.

    The patient I’m going to describe to you today is a 68-year-old male who came and saw me with moderate-to-severe atopic dermatitis that was involving his back, his hands, and his feet.

    The biggest symptom that he had was itch, which he described as controlling his life.

    He had failed prescription topical corticosteroids.

    He was also a groundskeeper at a golf course, so he was always in contact with different chemicals, and he was having to wear gloves, and that was difficult in the hot, humid weather here in Florida, because wearing those gloves in the hot weather just exacerbated the itch.

    Can you describe your patient’s treatment history and how it led you to prescribe DUPIXENT?

    When he met me, the only treatments he had been on were topical corticosteroids and IM cortisone injections and unfortunately he still had breakthrough and was relying on that IM cortisone injection.

    After that he wanted to talk a little bit more about DUPIXENT.

    When you prescribed DUPIXENT to your patient, what were your overall thoughts on DUPIXENT’s safety profile?

    The safety profile of all the medications that we prescribe patients is super important.

    [Narrator VO of on-screen adverse events; no captioning necessary]

    How did the fact that DUPIXENT is not an immunosuppressant and is not a steroid impact your opinion of DUPIXENT?

    My patients are so worried about any type of immunosuppressing type of medication and using steroids.

    Now they’re starting on, on DUPIXENT therapy; what did you see in this patient as far as improvement early on, like within the first few weeks of treatment?

    He had told me his itching had improved at about the 2- to 4-week mark. He’s been on DUPIXENT now, I believe, for approximately 9 months. At that 4-month mark to which I saw him, his skin was clear.

    But then I also asked him, how are things for you now? And his specific words were, “The atopic dermatitis is no longer controlling my life.”

    I know how exciting it is as a clinician, that the disease is being controlled rather than the disease controlling the patient.

    Thanks a lot, Gina. I think that was a great story and very well explained.

    Thank you so much and thank you for allowing me to share my patient’s story with you today.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi. I’m Dr Jim Del Rosso, and this is the Beyond the Surface series.

    Today on the green couch, we are very pleased to welcome Dr Brittany Craiglow, who is a board-certified dermatologist and a board-certified pediatric dermatologist who practices in Fairfield, Connecticut. Welcome, Brittany.

    So great to see you, Jim. Thanks for having me.

    We’re going to be talking about a disease state that is close to both of us: atopic dermatitis.

    So as a pediatric dermatologist I see a lot of it, and it, it’s actually one of my favorite things to treat.

    So Brit, can you tell us about the patient you want to discuss today?

    It’s a girl. She is now 10 years old. I met her when she was about 7. She has skin type probably 4 or 5. She had more moderate disease, I would say.

    Her mom was very clear that her itch was becoming increasingly problematic.

    You know, at 8 years old she was starting to have homework. She said she would look over while she was doing her math worksheet, or whatever, and see her scratching. She started to feel a little bit more self-conscious.

    In different patients, particularly those with darker skin types, often it looks a little bit different. It was hard to actually even see it. But she was covered in follicular eczema.

    So they hit that tipping point of being frustrated with everything previously.

    She had tried kind of everything under the sun. You name it, she had tried it.

    She was very itchy. Itch…you know, itchy night and day basically, and the family was feeling frustrated and really hoping that there might be something else for her to try.

    How did you explain why DUPIXENT was your next recommended step for their treatment?

    She had tried numerous topical corticosteroids of varying potencies and varying vehicles. She tried topical calcineurin inhibitors. And she remained, really, poorly controlled.

    When I said, “Look, there’s something beyond creams,” it was sort of like their eyes lit up. In fact, I say it’s not an immunosuppressant, it’s not a steroid.

    I try to explain the…the drug, the mechanism, the safety profile all first. Then I’ll say and, you know, because of the way the medicine works it needs to be delivered by an injection.

    [Narrator VO of on-screen adverse events; no captioning necessary]

    I think for me safety profile is, you know, probably actually the most important thing, especially when treating children. And to have a medicine that has a long-term safety profile like DUPIXENT, it is really, really welcome for me as a pediatric dermatologist.

    So now, DUPIXENT therapy’s been initiated.

    I saw her back. She said she was already less itchy at Week 16.

    Her skin was actually clear. And the family has just been really thrilled with her progress. And eczema isn’t at the forefront of decision-making.

    So that’s a great ending to the story about your patient and that they did well.

    Yeah, thank you so much for having me. It really was a pleasure. It’s always, you know, I think it’s even more fun to see these kids in real life, but a second best is to be able to talk about and share their stories.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi. I’m Dr Jim Del Rosso, and this is the Beyond the Surface series.

    Today on the green couch, we’re very pleased to have with us Dr Jenny Murase, who is a board-certified dermatologist practicing in Mountain View, California, and is also on faculty at the University of California-San Francisco in dermatology. Great to see you today, Jenny.

    It’s great to see you as well, Jim, and I’m so happy to be here. Atopic dermatitis is such an important topic, and it is a passion of mine. So I’m so glad to have this opportunity to talk to you today.

    Jenny, you’ve seen patients, most of them have had atopic dermatitis for a while and they’ve been on other treatments, have seen other clinicians. In that setting, what do you find to be the most challenging about treating these atopic dermatitis patients?

    Because I’m a consultative dermatologist, most of the patients referred to me are patients that other dermatologists were unable to treat effectively. So I would say the majority of my patients have moderate-to-severe disease.

    I care for a lot of patients with type 3 to 6 skin given that in the area that I practice, in the San Francisco Bay area, there are many patients that come from all over the world.

    And I think one thing that I’ve noticed over time when I’m caring for these medical consultative patients that come in with really recalcitrant disease and severe atopic dermatitis is oftentimes they go underdiagnosed. And I’ve grown to appreciate how important it is that the level of pigmentation in the skin can mask the degree of erythema and redness that is present in the skin. So unless we actually ask the right questions as dermatologists and find out how much they are itching, we will underdiagnose the patient.

    So it’s very important for our patients with skin of color with atopic dermatitis that we’re asking the right questions and we’re really doing our best to get an assessment of the severity of their pruritus.

    A lot of times as clinicians we’re thinking a lot of these things, but we’re not necessarily conveying it to the patient, so how would they really know the process that we’re going through? So we have to verbalize it.

    Also just asking, “Is this red for you? Do you feel like your skin is inflamed?” When the pigmentation is masking our ability to see the degree of erythema, we have to ask the right questions.

    Now let’s hear about the patient you want to discuss with us today.

    My patient was in her early 40s. She was the mother of 2 children, working within Silicon Valley. She had type 4 skin and she was half Malaysian, half Filipino. She had eczema since she was a child, and it did not remit during her teenage years. So she had it up until her early 40s and had really always struggled with it throughout her life.

    So what would you say was the most bothersome sign or symptom that she presented with?

    By far and away the most bothersome sign when she first presented was the degree of itch that she was experiencing. It was an incessant itch that felt like bees stinging her skin, and it was constant.

    What other treatments had your patient used before you started them on DUPIXENT?

    She had had atopic dermatitis throughout her entire life, ever since early childhood, so she had been on many prescription topical corticosteroids, prescription topical calcineurin inhibitors. She had taken oral immunosuppressant medication.

    DUPIXENT is not an immunosuppressant and it is not a corticosteroid.

    [Narrator VO of on-screen adverse events; no captioning necessary]

    Jenny, you’ve started DUPIXENT therapy for this patient. What did you see as far as the itch, the appearance of her skin? What did you observe, and what did she express to you?

    The itch had reduced dramatically, and just the decrease in the itch alone was the thing that I think that she was the most thrilled about.

    Because of the fact that she was darker pigmentation, it was more difficult for me to appreciate how red she truly was. It wasn’t until she had had skin that wasn’t involved with atopic dermatitis that she really truly understood the severity of her disease.

    Jenny, thanks so much for being here today to talk about atopic dermatitis and to share your patient’s story with us.

    Thank you so much for having me, because I know my patient is not alone. I know that there are thousands of people out there like her.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi. I’m Dr Jim Del Rosso, and this is the Beyond the Surface series.

    Today on the green couch, we are very pleased to welcome Lakshi Aldredge, who is a nurse practitioner practicing dermatology in Portland, Oregon. Lakshi, it’s great to see you today.

    It’s wonderful to be here, Jim. I’m looking forward to the conversation.

    Can you describe your role as a nurse practitioner and what your interactions are with the patients?

    Absolutely. I also have the good fortune again of working with my colleagues who include physicians, nurses, and other members of the healthcare team, and it really does sometimes take a village to care for patients with moderate-to-severe atopic dermatitis.

    My involvement includes asking how is it affecting their skin, what are the symptoms associated with it, and then having a fair and honest discussion about all of the different treatment options and then reassuring them that I am going to be with them throughout their journey of their disease, and ensuring that they are adhering to treatment.

    It’s always a unique situation when, as a provider, you can really empathize with the patient if you have also experienced the disease, which is the same case with me. I have had lifelong atopic dermatitis, much more severe as a child.

    Now let’s talk about the patient you’re going to discuss with us today, which I understand you’ve been seeing over some period of time. So it would be interesting to find out their journey.

    This is one of my favorite patients, and I’ve known him for many years. When I first met him, he was a 27-year-old Caucasian male, relatively newly married, who had suffered with lifelong atopic dermatitis.

    He had very moderate-to-severe, I would say severe disease, with most of the skin that was exposed very visibly affected, including his eyes. He did not make eye contact, and throughout the entire exam, that first interview, his wife answered the questions.

    So what bothered him the most? Did he have itching that bothered him the most? Was it the appearance of the condition that bothered him the most?

    Well, remember, in that first visit he was very itchy. He was scratching the entire time.

    So it sounds like this patient has been through quite a few treatments in the past by the time you saw them. Can you tell us the patient’s treatment history and how it led you to consider DUPIXENT at this point in time?

    It’s really important when talking with patients about DUPIXENT as a novel treatment option. My patient specifically had really used almost every treatment we have available for the treatment of moderate-to-severe uncontrolled atopic dermatitis. Those include topical moisturizers, topical anti-itch treatments, topical prescription corticosteroids.

    This therapy is perhaps different than the others because, with DUPIXENT, we do know the novel mechanism of action.

    So, I’d like to discuss the safety profile of DUPIXENT with you. How did that get brought into the discussion with them when you were talking about starting DUPIXENT therapy?

    It’s always important to have a fair and balanced discussion with all of my patients about any treatment. Specifically with DUPIXENT, we talk about a safety profile over the course of the clinical studies.

    [Narrator VO of on-screen adverse events; no captioning necessary]

    The fact that it does not include lab monitoring or require any lab monitoring at baseline or ongoing was also another factor.

    So now you’ve seen this patient back after initiating DUPIXENT. So, how would you describe changes that you’ve seen in their skin, in their symptoms?

    I was able to really see a lot of his skin and notice the improvement in the skin appearance.

    After initiating treatment with DUPIXENT, the number one improvement my patient noticed was the significant improvement in his itch, that it was much more decreased in intensity.

    It was great to talk to you today. A great conversation and an excellent case to teach about atopic dermatitis.

    Jim, thank you for having me and it’s always a pleasure to share our success stories of patients who live with chronic skin conditions and being able to demonstrate how therapy, appropriately prescribed and monitored, can truly help patients.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I’m Dr Neal Bhatia with the Beyond the Surface series.

    We’ve had a bunch of patients who’ve done well with DUPIXENT therapy, but there was one who stood out most recently. 

    And I remember him well. He’s 59 years old, he’s skin type five, and he just was absolutely covered in eczematous plaques and dryness and excoriation.

    You could tell he was really giving in to his disease and accepting where he was at. Even more so, just the sense of frustration that he has had nowhere to turn.

    I remember the first day when he came in.

    He talked about his skin as a prison. The redness, the thickness of his skin. He felt like his skin was broken.

    My patient made it pretty clear to us that the itch that he was experiencing was by far the most overwhelming issue that he had had. His coworkers—they were distracted by his scratching, thinking that he had something contagious in terms of shaking hands or saying hello, which kept reminding him of his condition.

    After we had enough time to discuss the journey with him, there was very little doubt that DUPIXENT was the therapy that we needed to get into his hands.

    We spent some time discussing with him about the safety profile.

    When we saw the patient back after his loading dose and his second injection, we really started to see a significant improvement in the EASI score and the amount of body surface area that was covered in severe plaques. And his description of itching and the urge to scratch was much more encouraging.

    He made it clear to us that being on DUPIXENT had changed the way he thought about his disease. He had described it as his enemy, as his jail.

    He felt like he had more control of his disease, more control of his itching, as he was the one giving himself the shots. He felt like he was actually more involved in his treatment. And that gave him a sense of encouragement in terms of how he was going to break the itch-scratch cycle himself.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I'm Dr Autumn Burnette with the Beyond the Surface series.

    I have a patient who’s in her late 30s. It’s a professional female. She has skin of color.

    I would describe the severity of this patient to be moderate-to-severe. She described the itch as being unbearable, and chronic, and throughout the day. And she even reported to me that she felt as if her skin was crawling.

    And my patient works in healthcare, so it was very concerning to her, not only cosmetically and the appearance of her skin being in the healthcare setting, but also the burden of having to frequently hand wash, which may even exacerbate her current moderate-to-severe condition.

    What I’ve observed in patients with skin of color is that it’s a more heterogeneous type of appearance of the lesions on the skin.

    She mentioned having lesions on her skin that were changing the actual pigment of her skin. And she even described to me that she didn’t even actually know the true pigment of her skin, because most of her skin was covered in atopic dermatitis lesions.

    She wanted my help and I actually had help to give her. I explained to her that DUPIXENT was an injectable monoclonal antibody that was a biological approach to managing her moderate-to-severe atopic dermatitis.

    When discussing the safety profile of DUPIXENT with my patients, I do explain to them that, of course, every patient responds to drugs differently.

    At her first follow-up, which was approximately four weeks after we started DUPIXENT, the patient mentioned to me that her itch level was greatly diminished, which I was excited for.

    She was able to expose her hands and arms. She was actually getting compliments from people about the appearance of her skin.

    I’ve been very excited to continue along this journey with her, and she has been excited about continuing DUPIXENT therapy.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I’m T.J. Chao with the Beyond the Surface series.

    So I have a 55-year-old patient who I’ve been seeing now for about 17 years, and he played in a cover band for a major rock group.

    He had moderate-to-severe atopic dermatitis that was affecting his body, his face, as well as his hands.

    So when my patient first came into the practice, he described his disease as unpredictable. He never knew when it was going to cause a problem. And it really affected his ability to play his music and feel comfortable.

    My patient would say that their skin was very red. It was thick, and the more he rubbed his skin, the thicker it became.

    But his worst complaint were his hands. His hands would essentially peel, scale. When he’s trying to play in the band, his fingers will literally crack and bleed while he’s on stage.

    My patient described itching that he would have just about at every point during the day. He would get up and try to put lotion on his skin throughout the night in order to feel better.

    He realized that he’s got to make a big change in the way he’s been treating his disease.

    When I described DUPIXENT to my patient, the goal and hope was it was going to help his skin—not only in the short-term, but also in the long-term. We had been treating his disease for so long episodically.

    With my patient, we talked about the risks and safety profile of DUPIXENT.

    When I prescribed DUPIXENT to my patient, within a few weeks he sensed a difference in his body.

    But what was most dramatic was the improvement in his hands and especially his fingertips. His hands were slightly red, but not eczematous as they were before. He was less itchy.

    I think the most pivotal point was when he went on a trip, and for the first time, he was sweating, he was hot on stage, the lights were beaming down on him. He looked a lot more comfortable. He realized that DUPIXENT was treating him not only on the outside—what he could see and feel—but it was also treating him on the inside.

    He realized that the disease was now under control. He has something that’s effective short- and long-term.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I’m Dr Jennifer Soung with the Beyond the Surface series.

    Of the patients that I’ve treated, one particular patient comes to mind. He’s an 8-year-old boy who is Southeast Asian and was referred to me by his pediatrician because of really stubborn disease.

    In skin of color, it can be harder to distinguish or make a diagnosis, because it may not look so typical. The plaques can be more lichenified and thicker, so may look like psoriasis.

    The appearance of the lesions are different as well in skin of color because the redness isn’t always so bright.

    Mom described it as his skin was on fire. Even, at times, she said it was like an active volcano. It was always brewing; he never had clear skin.

    He wanted to hide his eczema. Kids at school started to notice and would ask what was going on. Really, that sense of lack of control over his skin, his itching.

    As soon as the FDA approved it, I remember that day he was one of my first patients that I called. And the parents came right in. In this situation, the parents knew that they needed something more, and wanted to keep his inflammation and his atopic dermatitis controlled.

    When I prescribe DUPIXENT to my patient, I always share with them the most common adverse events.

    After starting DUPIXENT on his first visit back to the office, I didn’t even need to ask him how he was doing, because he just smiled at me. I knew that we were on the right path to healing his skin because he had described a relief in his itch. That was a big accomplishment.

    I’ve seen him improve over several weeks, and his skin healed really well. He was wearing short sleeves and shorts when he came to the office. He no longer felt like he had to cover all his skin.

    I remember Mom and Dad telling me it was like a huge weight that had been lifted off of them, because they saw that this medicine was actually helping relieve that itch and break that itch-scratch cycle.

    So the family, as well as the patient, have been thrilled. And even the little boy, my patient, says that the injection now is worth it.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I’m Dr Amy Spizuoco with the “Beyond the Surface” Series.

    This patient came into my office, 13-year-old female, who was fairly new to me.

    She was very soft-spoken and very quiet. She didn’t really have much to say because she was just so self-conscious and so uncomfortable. Her mother was her main advocate and let me know, “We have to do something to help her.”

    She really had this uncontrollable itch. She couldn’t stop. She was really uncomfortable at home, at school amongst her classmates and teachers…just that unsuppressible itch.

    She had lesions on different parts of her body that were extremely visible to her. And she just felt extremely uncomfortable in her skin.

    She had tried several different prescription steroid creams. So we came to the conclusion that DUPIXENT is going to be the choice for her.

    I really liked the fact that DUPIXENT is not an immunosuppressant or a steroid, because it makes me feel that the medicine is a different way of treating atopic dermatitis.

    In order to get my patient and her mother more comfortable with using a medication that’s an injection, I explained to them that injection therapy is not a new treatment to our armamentarium or to any of our patients.

    After my patient arrived to the office at Week 16, she came in smiling, sat down in the chair right away, and was ready to move on with treatment.

    After initiating treatment with DUPIXENT, she stated that the visibility of her lesions were much reduced and the itch intensity of her lesions were significantly reduced.

    While my patient has been on DUPIXENT for quite a while now, she told me she feels so much more comfortable in her skin and she’s a cheerleader.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    Hi, I’m Melodie Young with the Beyond the Surface series.

    I think about this young man sort of just entering middle age, who has had very few days of his life that he was not battling atopic dermatitis.

    When I asked this gentleman how this disease was affecting his life, his response was simple: It was his life. It’s how he spent all of his time, his energy. He told me that the itch was unrelenting.

    He talked about every decision that he made about what he was going to wear. Some friends were going over into east Texas camping, and he wanted to go, but he knew that they were probably going to want to swim. And he didn’t really want them to see his skin all over.

    I was hopeful that we had something that was going to be a major shift in his care.

    When you’re introducing DUPIXENT to a patient, what we have to do is to make sure that they also understand what the safety profile is.

    He started his shots and he came back to see me about 4 weeks later. And he said, “This is amazing.”

    He had on shorts. He became less itchy, more comfortable. And he wasn’t constantly thinking about his skin. His skin had healed in ways that he had never experienced.

    After my patient arrived to the office at Week 16, she came in smiling, sat down in the chair right away, and was ready to move on with treatment.

    He said, “Look at this. Before, I would never have let them see this much of my body, this much of my skin.”

    Now he was able to tell patients there is something that can help you.

    INDICATION AND IMPORTANT SAFETY INFORMATION
    Indication

    DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

    Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

    Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

    Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

    Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

    Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

    ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

    USE IN SPECIFIC POPULATIONS
    • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
    • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

    Please see accompanying full Prescribing Information.

    Providers are paid consultants.

    Hear from DUPIXENT patients

      INDICATION

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

       

      IMPORTANT SAFETY INFORMATION

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      Growing up, my skin was flaking, my skin was itching. My skin was red I would just scratch constantly, and the itching was something that I could never satisfy. Over time, my itching got less and less. After starting treatment, I started noticing some changes with my skin. I noticed that the irritation was reduced, and I noticed that the overall texture of my skin was smoother.

      Today, I feel like I can manage my atopic dermatitis symptoms and that is a huge relief! Of course, this is just my experience, and everyone’s experience with DUPIXENT will be different.

      INDICATION AND IMPORTANT SAFETY INFORMATION
      Indication

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

      IMPORTANT SAFETY INFORMATION

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      WARNINGS AND PRECAUTIONS

      Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

      Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

      Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

      Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

      Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

      Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

      Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

      ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

      USE IN SPECIFIC POPULATIONS
      • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
      • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

      Please see accompanying full Prescribing Information.

      INDICATION

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

       

      IMPORTANT SAFETY INFORMATION

       

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      I like the outdoors. It’s always been a part of my life. Growing up, I was an athlete and played a lot of outdoor sports. But I live with severe atopic dermatitis, and sometimes the outdoors and my eczema do not go well together. At any time, the heat, the sun, the sweat, could lead to flare-ups.

      It was hard when my friends would invite me to outdoor activities. I’d be thinking—okay…will my eczema flare up? What should I bring? How long should I stay outside? Should I even go? It was like a guessing game having to anticipate what my skin might do.

      But now, DUPIXENT is helping me manage my eczema. I feel I have control over my symptoms. My skin is clearer and I have less itch. Of course, everyone’s experience with DUPIXENT is different.

      Today, I am able to spend more time outdoors by worrying less about my skin. I still limit my time in the sun, but eczema is not my first thought when I go outside and that feels great.

      INDICATION AND IMPORTANT SAFETY INFORMATION
      Indication

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

      IMPORTANT SAFETY INFORMATION

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      WARNINGS AND PRECAUTIONS

      Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

      Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

      Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

      Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

      Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

      Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

      Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

      ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

      USE IN SPECIFIC POPULATIONS
      • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
      • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

      Please see accompanying full Prescribing Information.

      INDICATION

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

       

      IMPORTANT SAFETY INFORMATION

       

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      ANNIE:
      It was hard to not have a solution that worked for me. There was always something that I needed to do, always like a medicine I needed to take or a topical that I had to put on my skin.

      SUE:
      As a mom, I felt helpless, and we really felt out of control, and we needed to find something different that would work for her. Annie’s eczema specialist knew about DUPIXENT and thought that Annie was appropriate for it.

      ANNIE:
      Since starting DUPIXENT, my skin is a lot more clear. It’s a lot calmer.

      SUE:
      We did notice a difference within the first few weeks, and it has continually improved.

      ANNIE:
      My life doesn’t revolve around my skin anymore.

      SUE:
      Now, when she goes out and plays volleyball or hangs out with her friends, she can just be a kid, and that is a huge relief as a parent.

      INDICATION AND IMPORTANT SAFETY INFORMATION
      Indication

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

      IMPORTANT SAFETY INFORMATION

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      WARNINGS AND PRECAUTIONS

      Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

      Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

      Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

      Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

      Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

      Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

      Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

      ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

      USE IN SPECIFIC POPULATIONS
      • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
      • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

      Please see accompanying full Prescribing Information.

      INDICATION

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

       

      IMPORTANT SAFETY INFORMATION

       

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      I started to get these red, scaly patches on my skin. These red patches would itch constantly. To me, the itching felt like there were little tiny bugs underneath my skin, and they were just constantly crawling.

      After starting treatment with DUPIXENT, my open sores were able to heal, and my itching was going away.

      One day, I noticed I wasn’t constantly itching. I will never forget that time. I noticed my skin was getting clearer and smoother.

      Today, I’m still on treatment with DUPIXENT. I cherish every moment that I’m not bothered by the atopic dermatitis symptoms. Of course, this is just my experience. Everybody is unique, so someone else’s experience with DUPIXENT will be different.

      INDICATION AND IMPORTANT SAFETY INFORMATION
      Indication

      DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

      IMPORTANT SAFETY INFORMATION

      CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

      WARNINGS AND PRECAUTIONS

      Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

      Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

      Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

      Atopic Dermatitis Patients with Co-morbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

      Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

      Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

      Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

      ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.

      USE IN SPECIFIC POPULATIONS
      • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
      • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

      Please see accompanying full Prescribing Information.

      Actual patients treated with DUPIXENT. Individual results may vary.

      Download helpful resources about DUPIXENT for uncontrolled moderate-to-severe atopic dermatitis

      ADULTS (AGED 18+ YEARS)
      TREATED WITH DUPIXENT

      CHLOE'S PROFILE
      ARSALAN'S PROFILE

      ADOLESCENTS (AGED 12-17 YEARS) TREATED WITH DUPIXENT

      TYLER'S PROFILE
      ORE'S PROFILE

      CHILDREN (AGED 6-11 YEARS)
      TREATED WITH DUPIXENT

      HARPER'S PROFILE

      INFANTS TO PRESCHOOLERS
      (AGED 6 MONTHS TO 5 YEARS)
      PATIENT PROFILES

      SIENNA’S PROFILE
      JARED’S PROFILE

      DOSING INFORMATION
      FOR DUPIXENT
       

      DOWNLOAD AND SHARE

      Mark your calendars for
      these future events

      The Society for Pediatric Dermatology 2023 Annual Meeting

      July 13-16, 2023
      Asheville, NC

      American Academy of Dermatology Innovation Academy Meeting

      August 10-13, 2023
      Tampa, FL

      American College of Allergy, Asthma & Immunology Annual Scientific Meeting November 9-13, 2023
      Anaheim, CA

      Have more questions?
      Get answers.

      Visit the FAQ page to learn more about DUPIXENT and how it may be able to help patients.

      VISIT FAQs

      DUPIXENT MyWay is a patient support program that can help enable access
      to DUPIXENT and offers financial assistance for eligible patients, one-on-one
      nursing support, and more.

      LEARN HOW WE CAN HELP

      DUPIXENT MyWay
      ENROLLMENT FORMS
      FOR DERMATOLOGISTS
      English Enrollment Form
      Spanish Enrollment Form
      FOR ALLERGISTS
      English Enrollment Form
      Spanish Enrollment Form

      WATCH INFORMATIONAL VIDEOS ABOUT:

      ENROLLING IN DUPIXENT MyWay
      HOW DUPIXENT IS DELIVERED
      Contact a Field Representative
      Connect with a DUPIXENT Field Representative to get answers to your product-related questions and request samples.
      CONTACT A REP